The FDA approved venglustat (Infilbray) on Nov. 18, 2026, as the first treatment for the neurological symptoms of type 3 Gaucher disease. The once-daily tablet from Genzyme, a Sanofi company, crosses the blood-brain barrier, which standard enzyme infusions typically cannot.
Until this week, the answer to "what treats the brain disease in Gaucher type 3?" was no approved drug, as trial investigators wrote in Brain in 2023. Students now have an exception to learn. Residents in neurology, pediatrics, genetics and hematology get an approved option for ataxia and cognitive decline, plus three new safety warnings.
Infilbray is the FDA's 54th novel drug approval of 2026, per the agency's novel approvals list. No. 55, cemdisiran (Livsayis) for generalized myasthenia gravis, came the same day.
A pill beat infusions on ataxia and cognition in 43 patients
The approval rests on LEAP2MONO (NCT05222906), a phase 3, double-blind, double-dummy trial, according to Sanofi. It randomly assigned 43 patients aged 12 and older to one of two arms for 52 weeks. All had been on enzyme replacement therapy (ERT) for at least three years and had reached their systemic treatment goals.
- Venglustat arm: a venglustat tablet once daily plus a placebo infusion.
- ERT arm: intravenous imiglucerase every two weeks plus a placebo tablet.
The primary endpoint folded two scores into one prespecified global test: the modified Scale for Assessment and Rating of Ataxia (SARA) for coordination and balance, and the RBANS total score for cognition. Venglustat was superior to imiglucerase on that combined measure (p=0.0137), Sanofi said.
The label covers adults and children who weigh at least 15 kg (about 33 pounds), the FDA said. It had priority review and orphan drug designation; Sanofi says it also held breakthrough therapy, fast track and rare pediatric disease designations. European and Japanese reviews are under way.
Neurological symptoms had "remained beyond the reach of available therapies," said Dr. Pramod Mistry, director of the Yale Lysosomal Disease Center, in Sanofi's release. Mistry was also an author of the phase 2 trial report.
Why the brain was the hard part: replace the enzyme or shrink the substrate
Gaucher disease is autosomal recessive. Biallelic GBA1 mutations reduce lysosomal acid β-glucosidase (glucocerebrosidase) activity, so glucosylceramide and glucosylsphingosine build up, the LEAP investigators explain. It is the most common autosomal recessive disease in Ashkenazi Jewish populations, with a carrier frequency of about 6%, according to the StatPearls review.
Type 1 typically spares the brain. Type 2 is a severe, rapidly progressing infant form. Type 3 is the chronic neuropathic form, usually starting in childhood or adolescence, with signs such as horizontal ophthalmoplegia or supranuclear gaze palsy, ataxia and dystonia, as a 2024 LEAP patient-experience study lists them, plus myoclonus, seizures and dementia, per StatPearls.
There are two strategies. ERT replaces the missing enzyme, but it typically cannot reach the brain because of the blood-brain barrier, so it does not treat central nervous system disease in types 2 and 3, StatPearls notes. Substrate reduction therapy blocks glucosylceramide synthase, so cells make less of the lipid in the first place. Venglustat is a substrate reducer that crosses the blood-brain barrier, the FDA says.
| Drug | Strategy | Reaches the brain? | Use |
|---|---|---|---|
| Imiglucerase and other ERT | Replaces the enzyme by infusion | Typically not | Systemic (non-brain) features |
| Eliglustat | Substrate reduction | Not effectively | Type 1 only |
| Miglustat | Substrate reduction | Yes | Indicated only for mild to moderate type 1 in adults |
| Venglustat (Infilbray) | Substrate reduction, once-daily tablet | Yes | Neurological symptoms of type 3 |
For exams, the logic carries the question. Hepatosplenomegaly, pancytopenia, bone crises or an Erlenmeyer flask deformity, with Gaucher cells that look like wrinkled paper, point to Gaucher disease. A chronic course with eye-movement and coordination problems in a child or teen points to type 3. Then ask one thing: does the drug have to reach the brain?
Three warnings: mood, children's eyes and pregnancy
The label warns of suicidal ideation and behavior, lens opacification in pediatric patients and embryo-fetal toxicity, according to Sanofi. The FDA said the lens and fetal risks came from animal studies, and that gastrointestinal symptoms and effects on mood were the most frequent side effects.
In the trial's primary analysis, adverse reactions on venglustat (21 patients) vs imiglucerase (22 patients) included:
- Diarrhea: 14% vs 0%
- Nausea: 14% vs 5%
- Splenomegaly: 14% vs 0%
- Depression: 10% vs 0%
- Gastroenteritis: 10% vs 0%
- Vomiting: 10% vs 5%
The numbers are small: 14% of 21 patients is three people. Splenomegaly stands out because an enlarged spleen is a core sign of Gaucher disease itself, and neither release reports the trial's spleen or liver volume results.
What we don't know yet
- The size of the benefit. Sanofi released only the global test's p-value, not the change in each ataxia or cognition score. An open-label phase continues, with results to come.
- Alone or with ERT. LEAP2MONO tested venglustat in place of infusions in patients already stable on ERT. Neither release says whether the label pairs it with ERT; check the prescribing information.
- Younger children. The trial enrolled patients 12 and older; the label reaches children who weigh 15 kg. Neither release explains the evidence for that group.
- Whether biomarker drops mean better brains. In the phase 2 LEAP study, 11 adults taking venglustat 15 mg with imiglucerase saw median cerebrospinal fluid glucosylceramide fall 81% in a year, yet neurocognition on the Vineland II declined in every domain. The investigators called the signals "intriguing but intrinsically inconsistent."
- Price and launch date. Sanofi did not state them.
Practice-style reviews are in MedRise Board Review, and our last FDA story covered secukinumab for polymyalgia rheumatica. More resources are on the residents page.
Gaucher disease still teaches the same rule: infused enzymes stay out of the brain. Venglustat goes around that rule instead of through it, by cutting how much of the substrate gets made, including in the brain.
Sources
- FDA, approval announcement (Nov. 18, 2026)
- Sanofi, Infilbray U.S. approval release (Nov. 18, 2026)
- FDA, Novel Drug Approvals for 2026
- Schiffmann R et al., LEAP trial, Brain 2023
- Schiffmann R et al., Advances in Therapy 2024
- StatPearls, Gaucher Disease (NCBI Bookshelf)
- European Medicines Agency, Cerdelga (eliglustat) overview
MedRise Medical News summarizes public announcements and research for education only. It is not medical, legal or immigration advice.



